With its dengue vac­cine in the reg­u­la­to­ry queue, Take­da out­lines longterm fol­lowup da­ta that it says keep it out of Deng­vax­i­a's shad­ow

When Sanofi pub­lished longterm fol­lowup re­sults from a trio of Phase III tri­als for its dengue vac­cine in 2015, in­ves­ti­ga­tors flagged a con­cern­ing ob­ser­va­tion that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER